Ranibizumab Biosimilar, Human VEGF Monoclonal Antibody Fragment (Fab)

The humanized anti-VEGF-A monoclonal antibody drug Bevacizumab (trade name Avastin, Genentech/Roche) is the first clinically available angiogenesis inhibitor in the United States. The humanized anti-VEGF-A monoclonal antibody fragment (Fab) Ranibizumab (trade name Lucentis, Genentech) is derived from the same parent mouse antibody as bevacizumab. Both antibody drugs produce angiogenesis inhibition and slow the growth of new blood vessels. Ranibizumab is much smaller than the parent complete antibody but shows stronger binding to VEGF-A after affinity maturation. Ranibizumab can also be used to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss. Vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers.

Product Details
Species Reactivity	Human
Source	The ranibizumab biosimilar E.coli cell line
Host/Isotype	Recombinant Humanized Monoclonal Antibody Fragment (Fab)
Class	Monoclonal
Type	Antibody
Immunogen	The human VEGF-A
Clone	Ranibizumab Biosimilar
Conjugate	Unconjugated
Purity	>95%
Molecular Weight	49.19 kDa
Protein Concentration	1 mg/ml
Formulation	Liquid
Storage Condition	4°C for short time, -20°C or -80°C for long time.
Storage Buffer	0.2 uM filtered solution, pH 5.3